| Jul 29 |
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
|
| Jul 10 |
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
|
| May 30 |
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
|
| May 30 |
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
|
| May 21 |
BiomX (PHGE) Q1 2024 Earnings Call Transcript
|
| May 21 |
BiomX GAAP EPS of -$0.28
|
| May 21 |
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
|
